📰 Rezolute Inc News
Page 2 - Rezolute Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rezolute Inc. Real-time updates on events, politics, business and more.
February 18, 2024
Silverarc Capital Management LLC decreased its position in Rezolute, Inc. (NASDAQ:RZLT – Free Report) by 13.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 433,240 shares of the company’s stock after selling 66,304 shares during the period. Silverarc Capital Management LLC owned about 1.18% […]
February 13, 2024
13.02.2024 - Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access ...
January 24, 2024
REDWOOD CITY, Calif., Jan. 24, 2024 -- Rezolute, Inc. , a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare...
December 20, 2023
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS (Severe Low Back Pain)."
December 14, 2023
REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today
December 10, 2023
Caxton Corp reduced its holdings in Rezolute, Inc. (NASDAQ:RZLT – Free Report) by 6.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,318,967 shares of the company’s stock after selling 84,190 shares during the quarter. Rezolute accounts for 7.5% of Caxton Corp’s […]
November 18, 2023
Rezolute (NASDAQ:RZLT – Free Report) had its target price trimmed by JMP Securities from $8.00 to $7.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has a market outperform rating on the stock. A number of other analysts have also issued reports on RZLT. Cantor Fitzgerald reissued an overweight rating […]
November 17, 2023
REDWOOD CITY, Calif., Nov. 17, 2023 -- Rezolute, Inc. , a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases,...
October 17, 2023
REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today
October 15, 2023
Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) shares were down 2.6% during mid-day trading on Friday . The stock traded as low as $0.81 and last traded at $0.87. Approximately 51,270 shares were traded during mid-day trading, an increase of 58% from the average daily volume of 32,480 shares. The stock had previously closed at […]